A new study published in The Lancet reports that daily supplementation with Niagen, a patented form of nicotinamide riboside (NR), may help improve key symptoms in individuals with long COVID. In this first-of-its-kind clinical trial, participants taking Niagen showed meaningful increases in NAD+ levels—up to 3.1-fold after 5–10 weeks—alongside improvements in fatigue, sleep quality, mood and executive functioning when compared with their own baseline. Although differences between the Niagen and placebo groups did not reach statistical significance, researchers attribute this to the small sample size and high dropout rates. Importantly, Niagen was well tolerated with no major safety concerns. The findings suggest that restoring NAD+, a molecule essential for cellular energy and repair, may support recovery from long COVID, a condition marked by fatigue, cognitive issues and persistent post-viral symptoms. Larger, controlled trials are needed to clarify Niagen’s therapeutic potential and validate these early benefits.
Source : https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370%2825%2900567-X/fulltext
